Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Valencia
Clinical trial register · Spain

Clinical Trials in Valencia, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 111 Madrid 100 Valencia 42 Santiago Compostela 30 Seville 30
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Valencia61 AstraZeneca60 Novartis Pharmaceuticals42 Hoffmann-La Roche41 AbbVie39 Clear sponsor filter
Site location
Barcelona111 Madrid100 Valencia42 Santiago Compostela30 Seville30
All 75 locations
Target enrolment
to

Trials with a site in Valencia

42 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Active, closed
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
DrugsTNO155·Opnurasib·Trametinib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
25
Pamplona, Barcelona, Madrid, Valencia
2026-06-08
Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
NCT07456891Indication of the Parent Protocol
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
648
Barcelona, Alicante, Córdoba, Madrid, Valencia
2026-04-16
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Pamplona, Valencia, Barcelona, Seville
2026-03-26
Recruiting
Novartis Pharmaceuticals
Phase 2
30
Esplugues, Madrid, Valencia
2025-11-03
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Santiago Compostela, Huelva, El Palmar, Las Palmas GC, Madrid, Salamanca, Seville, Valencia
2025-10-03
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Pamplona, Valencia
2025-08-07
Recruiting
Novartis Pharmaceuticals
Phase 3
400
El Palmar, Valencia, Barcelona, Córdoba, Madrid, Málaga, Seville
2025-06-23
Active, closed
Novartis Pharmaceuticals
Phase 1/2
28
Barcelona, Córdoba, Madrid, Valencia
2025-02-24
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Barcelona, Lleida, Madrid, Málaga, Valencia
2025-02-07
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Cadiz, Badalona, Sabadell, Barcelona, Manises, Valencia, Madrid
2025-01-31
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Valencia
2024-10-17
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Málaga, Valencia, Barcelona, Madrid, Salamanca
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Salamanca, Valencia
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Santiago Compostela, L'Hospitalet de Llobregat, Alicante, Barcelona, Lleida, Madrid, Málaga, Valencia
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Sabadell, Bilbao, A Coruña, Madrid, Seville, Valencia
2024-06-28
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Santiago Compostela, Badalona, Santander, Barcelona, San Sebastian Reyes, Madrid, Valencia
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Granada, L'Hospitalet de Llobregat, Barcelona, El Palmar, Madrid, Seville, Valencia
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Cáceres, Córdoba, Madrid, Salamanca, Valencia
2024-03-07
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Santiago Compostela, Barcelona, Córdoba, Málaga, Seville, Valencia
2024-02-28
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Santiago, Granada, Barcelona, Alicante, Madrid, Valencia
2023-12-07
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Granada, Barcelona, Córdoba, Las Palmas GC, Valencia
2023-11-15
Recruiting
Novartis Pharmaceuticals
Phase 4
700
L'Hospitalet de Llobregat, Sabadell, Majadahonda, Barcelona, Madrid, Valencia
2023-08-14
Active, closed
Novartis Pharmaceuticals
Phase 3
100
Esplugues, Valencia
2023-07-11
Active, closed
Novartis Pharmaceuticals
Phase 1
123
Barcelona, Madrid, Valencia
2023-06-27
Active, closed
Novartis Pharmaceuticals
Phase 1
38
Valencia, Barcelona
2023-02-23
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Barcelona, Alicante, Las Palmas GC, Madrid, Valencia
2022-12-09
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Santander, Vigo, Barcelona, Córdoba, Madrid, Valencia
2022-08-04
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Santiago Compostela, Pamplona, Vigo, San Cristóbal de La Laguna, Valencia, Barcelona, Madrid
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 3
610
A Coruña, Barcelona, Córdoba, Madrid, Salamanca, Valencia
2022-07-08
Active, closed
Novartis Pharmaceuticals
Phase 3
469
Santiago Compostela, L'Hospitalet de Llobregat, El Palmar, Pamplona, Valencia, Barcelona, Madrid, Málaga
2021-06-15
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
L'Hospitalet de Llobregat, Sabadell, Majadahonda, El Palmar, Barcelona, Madrid, Valencia
2021-06-09
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia
2021-02-24
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Barcelona, Madrid, Sagunto, Seville, Valencia
2020-12-11
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Madrid, Valencia
2019-11-04
Active, closed
Novartis Pharmaceuticals
Phase 1
120
L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia
2019-10-30
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
Badalona, L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Salamanca, Seville, Valencia
2019-06-26
Active, closed
Novartis Pharmaceuticals
Phase 2
248
Granada, Sabadell, Manises, Barcelona, Las Palmas GC, Valencia
2019-02-27
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Barcelona, Madrid, Valencia
2018-01-26
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Donostia / San Sebastian, Barcelona, Madrid, Seville, Valencia
2017-08-23
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Esplugues, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia
2015-11-02
Active, closed
Novartis Pharmaceuticals
Phase 1/2
259
Madrid, Seville, Valencia
2013-10-22
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Vigo, Barakaldo, Madrid, Málaga, Seville, Valencia
2013-07-26
Rows per page Showing 1–42 of 42
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/valencia

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 42 of those studies with a site in Valencia that also match the filters currently applied.

How many clinical trials are recruiting in Valencia?

14 of the 42 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 28 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Valencia), 42 studies
PhaseStudiesRecruitingShare
Phase 323754.8%
Phase 28519%
Phase 1/25011.9%
Phase 1307.1%
Phase 4327.1%

Most active sponsors

Lead sponsors with the most studies (Valencia)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals4214
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.